- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
The Big Picture: Consolidating market rears its head again
The Big Picture: Consolidating market rears its head againBy Erik L. Ridley, EditorWho’s next? That’s the question many market watchers are asking following the latest spate of mergers and acquisitions in the rapidly consolidating PACS
The Big Picture:
Consolidating market rears its head again
By Erik L. Ridley, Editor
Whos next? Thats the question many market watchers are asking following the latest spate of mergers and acquisitions in the rapidly consolidating PACS sector. The power of this trend was evident in the last six weeks, when two long-time PACS market participants officially ceased to exist as independent firms.
While Applicare Medical Imagings prominent role as a PACS software developer appears secure in its new life as a subsidiary of GE Medical Systems (see story, page 2), the Olicon Imaging Systems brand name will soon be retired as part of its acquisition by ALI Imaging Systems, and the future of Olicons technology has yet to be determined.
The acquisitions continue market trends in evidence in other recent deals and corporate moves. ALI chose to acquire Olicon in large part to build its installed base, while GE pursued Applicare to broaden its product line to include support for teleradiology and miniPACS implementations, as well as to improve its geographical sales coverage.
GEs move to improve its entry-level PACS configurations is similar to Agfas efforts under way at its PACS software developer, Impax Technology (PNN 5/99).
While many believe that consolidation will only help the PACS sector in the long run, mergers and acquisitions can cause uncertainty and pain in the short term. As such, prospective PACS purchasers would be wise to ask vendors tough questions about their long-term commitment to this market.
- Search again
- Homepage
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
